NCT07114367 NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
| NCT ID | NCT07114367 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | NOBO Medicine |
| Condition | Non Hodgkin Lymphoma (NHL) |
| Study Type | INTERVENTIONAL |
| Enrollment | 9 participants |
| Start Date | 2025-12-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 9 participants in total. It began in 2025-12-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
Eligibility Criteria
Inclusion Criteria: 1. Age 19 to 80 years. 2. Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures. 3. Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma. 4. relapsed/refractory Patients who have received more than two prior lines of therapy. 5. Measurable disease based on Lugano classification. 6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. 7. Adequate organ function including: Exclusion Criteria: 1. Previous treatment with NB02 (poseltinib). 2. Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment). 3. Unable to take oral medication. 4. Inability to comply with study and follow-up procedures. 5. Concurrent use of other investigational drugs or enrollment in another clinical trial within 4 weeks prior to study drug administration. 6. Patients who have previously been treated with NB02 (poseltinib) or any other BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib). 7. Known HIV, HCV and HBV infection with active diseases
Frequently Asked Questions
Who can join the NCT07114367 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 80 Years, studying Non Hodgkin Lymphoma (NHL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07114367 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07114367 currently recruiting?
Yes, NCT07114367 is actively recruiting participants. Visit ClinicalTrials.gov or contact NOBO Medicine to inquire about joining.
Where is the NCT07114367 trial being conducted?
This trial is being conducted at Hwasun, South Korea, Seongnam, South Korea, Seoul, South Korea, Seoul, South Korea and 2 additional locations.
Who is sponsoring the NCT07114367 clinical trial?
NCT07114367 is sponsored by NOBO Medicine. The trial plans to enroll 9 participants.